Cargando…
A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis
BACKGROUND: An endovascular covered-stent has unique advantages in treating complex intracranial aneurysms; however, in-stent stenosis and late thrombosis have become the main factors affecting the efficacy of covered-stent treatment. Smooth-muscle-cell phenotypic modulation plays an important role...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086342/ https://www.ncbi.nlm.nih.gov/pubmed/33926468 http://dx.doi.org/10.1186/s12951-021-00867-8 |
_version_ | 1783686503207010304 |
---|---|
author | Liu, Yingjun Liu, Peixi Song, Yaying Li, Sichen Shi, Yuan Quan, Kai Yu, Guo Li, Peiliang An, Qingzhu Zhu, Wei |
author_facet | Liu, Yingjun Liu, Peixi Song, Yaying Li, Sichen Shi, Yuan Quan, Kai Yu, Guo Li, Peiliang An, Qingzhu Zhu, Wei |
author_sort | Liu, Yingjun |
collection | PubMed |
description | BACKGROUND: An endovascular covered-stent has unique advantages in treating complex intracranial aneurysms; however, in-stent stenosis and late thrombosis have become the main factors affecting the efficacy of covered-stent treatment. Smooth-muscle-cell phenotypic modulation plays an important role in late in-stent stenosis and thrombosis. Here, we determined the efficacy of using covered stents loaded with drugs to inhibit smooth-muscle-cell phenotypic modulation and potentially lower the incidence of long-term complications. METHODS: Nanofiber-covered stents were prepared using coaxial electrospinning, with the core solution prepared with 15% heparin and 20 µM rosuvastatin solution (400: 100 µL), and the shell solution prepared with 120 mg/mL hexafluoroisopropanol. We established a rabbit carotid-artery aneurysm model, which was treated with covered stents. Angiography and histology were performed to evaluate the therapeutic efficacy and incidence rate of in-stent stenosis and thrombosis. Phenotype, function, and inflammatory factors of smooth-muscle cells were studied to explore the mechanism of rosuvastatin action in smooth-muscle cells. RESULT: Heparin–rosuvastatin-loaded nanofiber scaffold mats inhibited the proliferation of synthetic smooth-muscle cells, and the nanofiber-covered stent effectively treated aneurysms in the absence of notable in-stent stenosis. Additionally, in vitro experiments showed that rosuvastatin inhibited the smooth-muscle-cell phenotypic modulation of platelet-derived growth factor-BB induction and decreased synthetic smooth-muscle-cell viability, as well as secretion of inflammatory cytokines. CONCLUSION: Rosuvastatin inhibited the abnormal proliferation of synthetic smooth-muscle cells, and heparin–rosuvastatin-loaded covered stents reduced the incidence of stenosis and late thrombosis, thereby improving the healing rates of stents used for aneurysm treatment. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-00867-8. |
format | Online Article Text |
id | pubmed-8086342 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80863422021-04-30 A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis Liu, Yingjun Liu, Peixi Song, Yaying Li, Sichen Shi, Yuan Quan, Kai Yu, Guo Li, Peiliang An, Qingzhu Zhu, Wei J Nanobiotechnology Research BACKGROUND: An endovascular covered-stent has unique advantages in treating complex intracranial aneurysms; however, in-stent stenosis and late thrombosis have become the main factors affecting the efficacy of covered-stent treatment. Smooth-muscle-cell phenotypic modulation plays an important role in late in-stent stenosis and thrombosis. Here, we determined the efficacy of using covered stents loaded with drugs to inhibit smooth-muscle-cell phenotypic modulation and potentially lower the incidence of long-term complications. METHODS: Nanofiber-covered stents were prepared using coaxial electrospinning, with the core solution prepared with 15% heparin and 20 µM rosuvastatin solution (400: 100 µL), and the shell solution prepared with 120 mg/mL hexafluoroisopropanol. We established a rabbit carotid-artery aneurysm model, which was treated with covered stents. Angiography and histology were performed to evaluate the therapeutic efficacy and incidence rate of in-stent stenosis and thrombosis. Phenotype, function, and inflammatory factors of smooth-muscle cells were studied to explore the mechanism of rosuvastatin action in smooth-muscle cells. RESULT: Heparin–rosuvastatin-loaded nanofiber scaffold mats inhibited the proliferation of synthetic smooth-muscle cells, and the nanofiber-covered stent effectively treated aneurysms in the absence of notable in-stent stenosis. Additionally, in vitro experiments showed that rosuvastatin inhibited the smooth-muscle-cell phenotypic modulation of platelet-derived growth factor-BB induction and decreased synthetic smooth-muscle-cell viability, as well as secretion of inflammatory cytokines. CONCLUSION: Rosuvastatin inhibited the abnormal proliferation of synthetic smooth-muscle cells, and heparin–rosuvastatin-loaded covered stents reduced the incidence of stenosis and late thrombosis, thereby improving the healing rates of stents used for aneurysm treatment. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-00867-8. BioMed Central 2021-04-29 /pmc/articles/PMC8086342/ /pubmed/33926468 http://dx.doi.org/10.1186/s12951-021-00867-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Liu, Yingjun Liu, Peixi Song, Yaying Li, Sichen Shi, Yuan Quan, Kai Yu, Guo Li, Peiliang An, Qingzhu Zhu, Wei A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis |
title | A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis |
title_full | A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis |
title_fullStr | A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis |
title_full_unstemmed | A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis |
title_short | A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis |
title_sort | heparin–rosuvastatin-loaded p(lla-cl) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086342/ https://www.ncbi.nlm.nih.gov/pubmed/33926468 http://dx.doi.org/10.1186/s12951-021-00867-8 |
work_keys_str_mv | AT liuyingjun aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT liupeixi aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT songyaying aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT lisichen aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT shiyuan aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT quankai aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT yuguo aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT lipeiliang aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT anqingzhu aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT zhuwei aheparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT liuyingjun heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT liupeixi heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT songyaying heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT lisichen heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT shiyuan heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT quankai heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT yuguo heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT lipeiliang heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT anqingzhu heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis AT zhuwei heparinrosuvastatinloadedpllaclnanofibercoveredstentinhibitsinflammatorysmoothmusclecellviabilitytoreduceinstentstenosisandthrombosis |